LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

AZN

81.26

-0.34%↓

Search

Kala Pharmaceuticals Inc

Geschlossen

13.72 -5.44

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

13.08

Max

14.42

Schlüsselkennzahlen

By Trading Economics

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+27.07% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

10. Nov. 2025

Kala Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Sept. 2025, 23:37 UTC

Heiße Aktien

Stocks to Watch: Oracle, Wearable Devices, GameStop

9. Sept. 2025, 20:41 UTC

Ergebnisse

Oracle's Backlog Surges With Major Customer Deals in 1Q

9. Sept. 2025, 20:30 UTC

Ergebnisse

GameStop 2Q Sales, Profit Rise

9. Sept. 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9. Sept. 2025, 21:35 UTC

Ergebnisse

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 21:32 UTC

Ergebnisse

Oracle's Backlog Swells With Big Customer Deals -- Update

9. Sept. 2025, 21:02 UTC

Akquisitionen, Fusionen, Übernahmen

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Sept. 2025, 20:33 UTC

Ergebnisse

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9. Sept. 2025, 20:26 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:23 UTC

Ergebnisse

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9. Sept. 2025, 20:12 UTC

Ergebnisse

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9. Sept. 2025, 20:10 UTC

Ergebnisse

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9. Sept. 2025, 20:09 UTC

Ergebnisse

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle 1Q Operating Income Was $4.3 B >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9. Sept. 2025, 20:08 UTC

Ergebnisse

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9. Sept. 2025, 20:07 UTC

Ergebnisse

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Software Revenue $5.72B >ORCL

9. Sept. 2025, 20:06 UTC

Ergebnisse

Synopsys 3Q Adj EPS $3.39 >SNPS

9. Sept. 2025, 20:06 UTC

Ergebnisse

Oracle 1Q Cloud Revenue $7.19B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Rev $14.93B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q EPS $1.01 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Synopsys 3Q EPS $1.50 >SNPS

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Services Revenue $1.35B >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Adj EPS $1.47 >ORCL

9. Sept. 2025, 20:05 UTC

Ergebnisse

Oracle 1Q Hardware Revenue $670M >ORCL

Peer-Vergleich

Kursveränderung

Kala Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

27.07% Vorteil

12-Monats-Prognose

Durchschnitt 18.4 USD  27.07%

Hoch 30 USD

Tief 12 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Kala Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

5

Buy

0

Halten

0

Sell

Finanzen

$

Über Kala Pharmaceuticals Inc

Kala Pharmaceuticals Inc
help-icon Live chat